Copyright
©The Author(s) 2017.
World J Hepatol. Dec 28, 2017; 9(36): 1322-1331
Published online Dec 28, 2017. doi: 10.4254/wjh.v9.i36.1322
Published online Dec 28, 2017. doi: 10.4254/wjh.v9.i36.1322
Variable | Overall (110) |
Age (yr) | 67.5 (41-80) |
Gender | |
Male | 91 (82.7) |
Female | 19 (17.3) |
Etiology of liver disease | |
Viral (HBV/HCV/HBV and HCV) | 70 (63.6) |
Alcohol | 17 (15.5) |
NASH/NAFLD | 14 (12.7) |
Viral and alcohol | 9 (8.2) |
PS | |
0 | 33 (30) |
1 | 64 (58.2) |
2 | 13 (11.8) |
Diabetes | |
No | 87 (79.1) |
Yes | 23 (20.9) |
Child-Pugh score | |
A | 82 (74.5) |
B | 28 (25.5) |
N nodules | |
Single | 35 (31.8) |
2-3 | 20 (18.2) |
> 3 or infiltrating | 55 (50) |
Maximum size | |
≤ 5 cm | 56 (50.9) |
> 5 cm | 54 (49.1) |
Macrovascular invasion | |
No | 60 (54.5) |
Yes | 50 (45.5) |
Extrahepatic spread | |
No | 91 (82.7) |
Yes | 19 (17.3) |
Macrovascular invasion and/or extrahepatic spread | |
No | 49 (44.5) |
Yes | 61 (55.5) |
NIACE | |
≤ 3 | 84 (76.4) |
> 3 | 26 (23.6) |
AFP | |
≤ 200 ng/mL | 74 (67.3) |
> 200 ng/mL | 36 (32.7) |
Treatment before BCLC C diagnosis | |
No | 53 (48.2) |
Yes | 57 (51.8) |
Type of treatment before BCLC C diagnosis (one or more per patient) | |
TACE | 35 |
Surgical resection | 20 |
RFA | 18 |
Sorafenib | 13 |
PEI | 11 |
TACE + RFA | 8 |
TARE | 4 |
DSM-TACE | 1 |
Number of treatments after BCLC C diagnosis | |
None | 22 (20) |
Single | 32 (29.1) |
Multiple | 56 (50.9) |
Type of treatment after BCLC C diagnosis (one or more per patient) | |
Sorafenib | 53 |
TACE | 25 |
TARE | 18 |
Second line systemic agent | 15 |
PEI | 12 |
DSM-TACE | 5 |
LT | 3 |
RFA | 1 |
Best tumor response | |
CR | 10 (9.1) |
PR | 21 (19.1) |
SD | 12 (10.9) |
PD | 67 (60.9) |
DC | |
No | 67 (60.9) |
Yes | 43 (39.1) |
- Citation: Ponziani FR, Spinelli I, Rinninella E, Cerrito L, Saviano A, Avolio AW, Basso M, Miele L, Riccardi L, Zocco MA, Annicchiarico BE, Garcovich M, Biolato M, Marrone G, De Gaetano AM, Iezzi R, Giuliante F, Vecchio FM, Agnes S, Addolorato G, Siciliano M, Rapaccini GL, Grieco A, Gasbarrini A, Pompili M. Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma. World J Hepatol 2017; 9(36): 1322-1331
- URL: https://www.wjgnet.com/1948-5182/full/v9/i36/1322.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i36.1322